Risperidone for autism spectrum disorder

Jesner, OS; Aref‐Adib, Mehrnoosh; Coren, Esther

doi:10.1002/14651858.cd005040

Cited by 38 publications

(50 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Risperidone is the only drug that has been approved by the FDA to treat the symptoms (irritability) of autism. A review published in the Cochrane Library examined three randomized controlled trials (Jesner et al 2007). Meta-analysis indicated the drug was effective in treating the symptoms of irritability and aggression.…”

Section: Pharmacological Treatmentsmentioning

confidence: 99%

Neurofeedback for Autistic Spectrum Disorder: A Review of the Literature

Coben¹,

Linden

Myers

2009

Appl Psychophysiol Biofeedback

154

View full text Add to dashboard Cite

There is a need for effective interventions to address the core symptoms and problems associated with autistic spectrum disorder (ASD). Behavior therapy improves communication and behavioral functioning. Additional treatment options include psychopharmacolog-ical and biomedical interventions. Although these approaches help children with autistic problems, they may be associated with side effects, risks or require ongoing or long-term treatment. Neurofeedback is a noninvasive approach shown to enhance neuroregulation and metabolic function in ASD. We present a review of the literature on the application of Neurofeedback to the multiple problems associated with ASD. Directions for future research are discussed.

show abstract

Section: Pharmacological Treatmentsmentioning

confidence: 99%

Neurofeedback for Autistic Spectrum Disorder: A Review of the Literature

Coben¹,

Linden

Myers

2009

Appl Psychophysiol Biofeedback

154

View full text Add to dashboard Cite

show abstract

“…All the PMHD except the intellectual disability, need pharmacological treatment (see accompanying paper) and can be effectively treated in the primary care setting if the pediatrician is comfortable with the use of five psychotropic medications at the appropriate dose at appropriate dosing schedules (Table 2) [19][20][21][22][23][24][25][26][27][28][29]. Knowledge of psychotropic medications which are preferred for use in this population allows primary care physicians to make timely and successful therapeutic interventions.…”

Section: Medication Choice Interactions and Side Effectsmentioning

confidence: 99%

“…Summary of pharmacological treatment for the Priority Mental Health Disorders in primary care pediatric setting[19][20][21][22][23][24][25][26][27][28][29] Level Ia: Evidence obtained from meta-analysis of randomized controlled trials;Level Ib: Evidence obtained from at least one randomized controlled trial Level IIa: Evidence obtained from at least one well-designed controlled study without randomization Level IIb: Evidence obtained from at least one other type of well-designed quasi-experimental study…”

mentioning

confidence: 99%

Priority Mental Health Disorders of Children and Adolescents in Primary-care Pediatric Settings in India 2: Diagnosis, Pharmacological Treatment and Referral

Russell

Nair²,

Mammen

et al. 2011

Indian J Pediatr

View full text Add to dashboard Cite

The advent of pediatric psychopharmacology has enormously improved psychiatric care of children and adolescents. Nonetheless, our practice of diagnosis, treatment and referral in primary-care pediatric settings is not optimum as current evidence based knowledge is not regularly applied in the actual clinical circumstances. To help primary-care pediatricians minimise this in research-clinical practice, pharmacological treatment and referral in their clinical practice, they need to follow a two-tier diagnostic and multi axial treatment approach. The two-tier diagnostic approach of using a screening measure followed by confirmation of the screen positive cases with reference standard clinical criterion, improves the sensitivity and specificity. The multiaxial treatment has the advantage of offering a holistic approach to the intervention and improve prognosis from the interacting axes. The primary-care physician should be aware of the medications of choice for the Priority Mental Health Disorders and their drug interactions. Finally, referral of cases with atypical presentations, multiple comorbidities and poor response to the first-line of treatment needs referral to the next tier in the system.

show abstract

“…Medication trials have been performed with various medications and aimed at different target symptoms. Most trials are open-label studies and case reports, and there is only a limited number of randomised control trials (RCTs) [69,110]. Risperidone has been demonstrated to be beneficial for irritability, repetitive behaviours and aggression, but a significant effect on social-communicative features has not been demonstrated [93].…”

Section: Behavioural Treatmentsmentioning

confidence: 99%

What’s new in autism?

Steyaert

Marche

2008

Eur J Pediatr

View full text Add to dashboard Cite

This review on autism spectrum disorder (ASD) focusses on recent insights in the clinical picture, such as continuity of the phenotype and the concept of broader phenotype, on epidemiology and on clinical issues relevant to physicians, including new methods for early screening and diagnosis, psychiatric and somatic co-morbidity, and the expansion of so-called complementary and alternative treatments. ASD is a disorder with mainly genetic causes and recent insights show that a variety of genetic mechanisms may be involved, i.e. single gene disorders, copy number variations and polygenic mechanisms. Technological advances in genetics have lead to a number of promising findings, which, together with other lines of fundamental research, suggest that ASD may be a disorder of connectivity in the brain, at least in a subgroup of patients. It is possible that part of the genetic load in autism actually reflects gene-environment interaction, but there is no evidence for purely environmental causes in a substantial number of cases. Clinical research suggests that ASD may be a multi-system disorder in at least a subgroup of subjects, affecting the gastro-intestinal (GI) tract, the immune system and perhaps other systems. Behavioural treatments remain the cornerstone of management, and are mainly aimed at stimulation of the domains of impaired development and reducing secondary behaviours. These treatments are constantly being refined, but the main progress in this area may be the increase of research on effectiveness.

show abstract

Risperidone for autism spectrum disorder

Cited by 38 publications

References 14 publications

Neurofeedback for Autistic Spectrum Disorder: A Review of the Literature

Neurofeedback for Autistic Spectrum Disorder: A Review of the Literature

Priority Mental Health Disorders of Children and Adolescents in Primary-care Pediatric Settings in India 2: Diagnosis, Pharmacological Treatment and Referral

What’s new in autism?

Contact Info

Product

Resources

About